CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage

The CDC expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from RSV .

Beyfortus is a monoclonal antibody from Sanofi U.S. AstraZeneca that won approval in August.

RSV is a Beyfortus spiratory infection that usua Sanofi uses AstraZeneca like sympto RSV but can present as more severe cases in children the holiday season one yFee two ighLightText__NxlGi">RSVU.S. Covid last The Centers for Disease Control and Prevention tText__NxlGi">RSV more than 77,000 maryFeed_highLightText__NxlGi">U.S. CDC U.S. Gi">l CDC winter< late Thursday class="summaryFeed_highLightText Beyfortus the week ended Nov. 4 Sanofi clas AstraZeneca eed_highLightText__Nxl August S. RSV an class="summaryFeed_highLightText__NxlGi">Nearly the holiday season an class="summ one Feed two ghLightText__NxlGi">the middl U.S. October RSV U AstraZeneca Nirav ShahCDC > Hospitals d_highLightText__NxlGi">CDC Beyfortus ed_highLightT Sanofi xlGi">FDA CDC early 2024 the en RSV f RSV s year the Food and Drug Administration Each year an> a few hundred ighLightText__NxlGi">CD 5 6,000 to 10,000 "summaryFeed_highLightText_ CDC lG RSV CDC < around 58,000 to 80,000 _highLightText__NxlGi">each year 5 years old